Abstract
New therapies, in particular the tumor necrosis factor-alpha-blocking drugs, have led to improved control of inflammation in rheumatoid arthritis for a proportion of patients. There remains a need for therapies for patients who do not respond to these drugs or in whom they are contraindicated or not tolerated. There is evidence that T cells are involved in the initiation and perpetuation of rheumatoid arthritis. Abatacept is the first in a new class of drugs targeted at T-cell function in autoimmune disease: the costimulation blockers. It has shown safety and efficacy in rheumatoid arthritis. Further trials of this and other costimulation blockers are in progress in rheumatoid arthritis and other diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.